抗ミュラーリアンホルモン検査市場：製品、成分、用途、エンドユーザー別-2025-2030年世界予測

抗ミュラーリアンホルモン検査市場は、2024年には3億541万米ドルとなり、2025年には3億4,021万米ドル、CAGR11.48%で成長し、2030年には5億8,648万米ドルに達すると予測されています。

抗ミュラーホルモン（AMH）検査は、卵巣予備能と受胎可能性に関する重要な洞察を提供し、女性の生殖に関する健康評価の要として浮上してきました。個別化医療と高度な診断技術が臨床判断を後押しする時代において、AMH検査は卵巣機能を評価する重要なツールを臨床医と患者の双方に提供しています。本レポートでは、AMH検査市場の進化するダイナミクスを探求し、科学的・技術的なブレークスルーだけでなく、患者のケアや治療結果に対するより広範な意味合いについても論じています。

過去数年間で、アッセイの感度と特異度が飛躍的に向上し、検査の状況は一変しました。研究開発により、AMH検査は多嚢胞性卵巣症候群（PCOS）や早発卵巣不全などの病態を理解するための貴重な診断マーカーとしての役割を確固たるものとしました。さらに、早期診断と早期介入の利点に関するヘルスケア提供者の意識の高まりが、検査プロトコルの広範な採用につながっています。この包括的なサマリーは、市場促進要因・課題・機会を詳細に考察し、意思決定者や専門家を問わずバランスの取れた視点を提供します。

現在の動向、技術の進歩、市場セグメンテーションを研究することで、このサマリーは利害関係者に、急速に進化する業界をナビゲートするために必要な洞察力を提供します。以下の考察は、この市場における戦略的シフトと、将来の成長に対するその意味を理解するための基礎を築くものです。

抗ミュラーリアンホルモン検査市場の変革

近年、AMH検査の状況は、先進技術、臨床ガイドラインの進化、患者の期待の変化などにより、大きく変化しています。アッセイ開発における革新は、診断検査の信頼性とスピードの両方を向上させ、それによって所要時間を短縮し、臨床転帰を改善しました。かつては労働集約的なプロセスに依存していた手法も、現在では自動化とデジタル統合の恩恵を受け、ワークフローが合理化され、データの精度が向上しています。

規制当局の承認プロセスはより強固で透明なものとなり、新しい検査方法が厳しい品質と安全性の基準を満たしていることが保証されるようになりました。このシフトは、医療従事者に大きな信頼を与えるだけでなく、新しい検査キットや検査機器の採用にも道を開きます。一方、診断薬メーカーと研究機関とのコラボレーションは、継続的なイノベーションの環境を促進しています。このようなパートナーシップは、科学的発見の実用的な診断ツールへの転換を加速します。

さらに、市場参入企業は利便性と精度の両方を重視した患者中心のソリューションにますます注力しています。新たなテクノロジーは、ポイントオブケア検査やセルフチェックキットのニーズに対応し、従来の臨床現場以外でも診断がより身近なものとなっています。このような業界全体の変化は、検査の実施方法に革命をもたらすだけでなく、主要市場プレイヤーの戦略的優先順位を再調整し、よりダイナミックで競合情勢の舞台を整えつつあります。

AMH検査市場の主要セグメンテーションインサイト

詳細なセグメンテーション分析により、AMH検査市場を形成するいくつかの極めて重要な要因が明らかになりました。最初のセグメンテーションでは、製品をポイントオブケア（POC）検査やセルフチェックキットなどのカテゴリーに分け、それぞれ異なるユーザー要件や設定をターゲットとしています。このような製品ベースのセグメンテーションは、臨床環境と家庭での検査シナリオの両方に対応する、迅速でアクセスしやすいソリューションを提供することの重要性を強調しています。

コンポーネントの観点からは、分析では機器と試薬・キットを区別しています。機器はベンチトップ型とポータブル型に細分化され、市場が精密検査機器と様々なヘルスケア環境に適したモバイル診断ソリューションに注力していることを強調しています。同時に、試薬とキットのセグメントには、カスタマイズされたアッセイと標準的なアッセイの両方が含まれます。この区別は、広く適用可能な標準検査キットとともに、特定の臨床ニーズに対応したオーダーメイドの診断ソリューションを開発するという二重のアプローチを強調するものです。

アプリケーションを考慮すると、市場は主に卵巣予備能評価、多嚢胞性卵巣症候群診断、早発卵巣不全予測におけるAMH検査の役割によって牽引されます。各アプリケーションは、患者の生殖に関する健康状態について独自の洞察を提供し、特定の分析アプローチと精度レベルを要求します。最後に、エンドユーザー区分では、診断研究所、不妊治療クリニック、病院、研究機関をまとめています。この分類は、関係者の多様なエコシステムを示しており、それぞれがユニークな要求と運営上の課題を抱えているため、個別の市場セグメントに合わせたさまざまな革新的ソリューションが推進されています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 生殖に関する健康問題と不妊症の増加により、AMH検査の需要が高まっています。
    • 政府の取り組みと有利な償還政策がAMH検査の普及を後押し
    • 妊娠後期の傾向が高まるにつれ、信頼できる妊娠力指標の必要性が高まっています。
  • 抑制要因
    • 高い運用コストと限定的な償還ポリシーが、抗ミュラーリアンホルモン検査市場
  • 機会
    • より広範な不妊治療情勢における個別化医療に不可欠なツールとしてAMH検査を推進する
    • AMH検査の予約と結果管理をシームレスに行うデジタルプラットフォームを強化し、ユーザーエクスペリエンスを向上
  • 課題
    • 抗ミュラー管ホルモン検査の拡大に影響を与える重要な規制
• 市場セグメンテーション分析
  • 製品：利便性と個人の健康管理のためのセルフチェックキットの需要増加
  • 応用：不妊問題の増加に伴い、抗ミュラー管ホルモン検査による卵巣予備能評価の適用が拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 抗ミュラーリアンホルモン検査市場：製品別

• POCテスト
• セルフチェックキット

第7章 抗ミュラーリアンホルモン検査市場：コンポーネント別

• 機器
  • ベンチトップデバイス
  • ポータブルアナライザー
• 試薬とキット
  • カスタマイズアッセイ
  • 標準アッセイ

第8章 抗ミュラーリアンホルモン検査市場：用途別

• 卵巣予備能評価
• 多嚢胞性卵巣症候群の診断
• 早産卵巣不全の予測

第9章 抗ミュラーリアンホルモン検査市場：エンドユーザー別

• 診断検査室
• 不妊治療クリニック
• 病院
• 調査機関

第10章 南北アメリカの抗ミュラーリアンホルモン検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の抗ミュラーリアンホルモン検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの抗ミュラーリアンホルモン検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbexa Limited
• Ansh Labs LLC
• Athenese-Dx
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• bioMerieux S.A.
• BioVendor-Laboratorni Medicina A.S.
• Chengdu VACURE Biotechnology Co., Ltd.
• CTK Biotech, Inc.
• Cusabio Technology LLC
• Danaher Corporation
• Eagle Biosciences, Inc.
• Elabscience Bionovation Inc.
• Epitope Diagnostics, Inc.
• F. Hoffmann-La Roche Ltd.
• Fujirebio Europe N.V. by H.U. Group Holdings, Inc.
• Goldsite Diagnostics Inc.
• Healthy Human Labs Limited（Vitall）
• Kamiya Biomedical Company
• LifeSpan BioSciences, Inc.
• London Gynaecology Limited
• Meridian Bioscience, Inc.
• Monobind Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Tosoh Corporation
• Vitrosens Biotechnology Co., Ltd.

LIST OF FIGURES

• FIGURE 1. ANTI-MULLERIAN HORMONE TEST MARKET MULTI-CURRENCY
• FIGURE 2. ANTI-MULLERIAN HORMONE TEST MARKET MULTI-LANGUAGE
• FIGURE 3. ANTI-MULLERIAN HORMONE TEST MARKET RESEARCH PROCESS
• FIGURE 4. ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANTI-MULLERIAN HORMONE TEST MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-MULLERIAN HORMONE TEST MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 50. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 51. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 81. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 82. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 83. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 84. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 87. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 88. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 89. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 90. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 152. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 190. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 191. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 192. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 193. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 214. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 215. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 216. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 217. POLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 219. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 220. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 221. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 222. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 223. QATAR ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 224. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 242. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 243. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 248. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 249. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 254. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 255. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 260. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 261. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 266. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 267. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 272. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 278. ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 279. ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, 2024

The Anti-Mullerian Hormone Test Market was valued at USD 305.41 million in 2024 and is projected to grow to USD 340.21 million in 2025, with a CAGR of 11.48%, reaching USD 586.48 million by 2030.

The anti-mullerian hormone (AMH) test has emerged as a cornerstone in the assessment of female reproductive health, offering critical insights into ovarian reserve and fertility potential. In an era where personalized medicine and advanced diagnostic techniques are driving clinical decisions, the AMH test provides both clinicians and patients with a significant tool for evaluating ovarian function. This report explores the evolving dynamics of the AMH testing market, discussing not only the scientific and technological breakthroughs but also the broader implications on patient care and treatment outcomes.

Over the past few years, significant strides in assay sensitivity and specificity have transformed the testing landscape. Research and development have cemented the role of the AMH test as an invaluable diagnostic marker for understanding conditions such as polycystic ovary syndrome (PCOS) and premature ovarian failure. Moreover, increasing awareness among healthcare providers about the benefits of early diagnosis and intervention has led to broader adoption of testing protocols. This comprehensive summary offers an in-depth look at market drivers, challenges, and opportunities, providing a balanced perspective that caters to decision-makers and experts alike.

By studying current trends, technological advancements, and market segmentation, this summary equips stakeholders with the necessary insights to navigate a rapidly evolving industry. The discussion that follows lays the foundation for understanding the strategic shifts within this market and their implications for future growth.

Transformative Shifts in the Testing Landscape

Recent years have witnessed transformative shifts in the AMH testing landscape, driven by advanced technologies, evolving clinical guidelines, and changing patient expectations. Innovations in assay development have enhanced both the reliability and speed of diagnostic tests, thereby reducing turnaround times and improving clinical outcomes. Methodologies that once relied on labor-intensive processes now benefit from automation and digital integration, leading to streamlined workflows and improved data precision.

Regulatory approval processes have become more robust and transparent, ensuring that new testing methods meet stringent quality and safety standards. This shift not only instills greater confidence among healthcare providers but also paves the way for the adoption of novel test kits and instruments. Meanwhile, collaborations between diagnostic companies and research institutions are fostering an environment of continuous innovation. Such partnerships accelerate the translation of scientific discoveries into practical diagnostic tools.

Furthermore, market entrants are increasingly focused on patient-centered solutions that emphasize both convenience and accuracy. Emerging technologies cater to the need for point-of-care testing and self-check kits, making diagnostics more accessible outside traditional clinical settings. These industry-wide changes are not only revolutionizing the way tests are performed but are also realigning the strategic priorities of key market players, setting the stage for a more dynamic and competitive landscape.

Key Segmentation Insights in the AMH Testing Market

A detailed segmentation analysis reveals several pivotal factors shaping the AMH testing market. The first segmentation divides products into categories such as point-of-care (POC) testing and self-check kits, each targeting different user requirements and settings. Such product-based segmentation underscores the importance of offering rapid, accessible solutions that cater both to clinical environments and at-home testing scenarios.

From a component perspective, the analysis differentiates between instruments and reagents & kits. Instruments are sub-segmented into benchtop devices and portable analyzers, highlighting the market's focus on precision laboratory instruments as well as mobile diagnostic solutions suited to a variety of healthcare settings. Concurrently, the reagents and kits segment encompasses both customized assays and standard assays. This distinction emphasizes the dual approach of developing tailored diagnostic solutions that meet specific clinical needs alongside widely applicable standard test kits.

When considering applications, the market is primarily driven by the roles of the AMH test in ovarian reserve assessment, polycystic ovary syndrome diagnosis, and premature ovarian failure prediction. Each application offers unique insights into a patient's reproductive health, demanding specific analytical approaches and levels of accuracy. Finally, the end-user segmentation brings together diagnostic laboratories, fertility clinics, hospitals, and research institutes. This classification showcases the diverse ecosystem of stakeholders involved, each with unique demands and operational challenges, thus driving a range of innovative solutions tailored to distinct market segments.

Based on Product, market is studied across POC Testing and Self-check Kits.

Based on Component, market is studied across Instruments and Reagents & Kits. The Instruments is further studied across Benchtop Devices and Portable Analyzers. The Reagents & Kits is further studied across Customized Assays and Standard Assays.

Based on Applications, market is studied across Ovarian Reserve Assessment, Polycystic Ovary Syndrome Diagnosis, and Premature Ovarian Failure Prediction.

Based on End User, market is studied across Diagnostic Laboratories, Fertility Clinics, Hospitals, and Research Institutes.

Key Regional Insights and Market Dynamics

Geographical insights are crucial in understanding the global dynamics of the AMH testing market. The analysis highlights distinct regional trends, with the Americas being characterized by well-established healthcare infrastructures coupled with high patient awareness and rapid adoption of advanced diagnostic technologies. In contrast, the Europe, Middle East & Africa region presents a blend of mature markets and emerging economies where regulatory reforms and increasing investment in healthcare are driving market expansion.

The Asia-Pacific region offers substantial growth opportunities due to its vast population, rising income levels, and a growing focus on women's health. Innovations in diagnostic technologies and improvements in healthcare accessibility are helping bridge the gap between urban and rural healthcare services. These regions exhibit unique market behaviors and growth trajectories influenced by local economic conditions, regulatory environments, and cultural perceptions regarding health and wellness.

Understanding these regional nuances is essential for companies aiming to tailor their strategies and for stakeholders seeking to capitalize on untapped market potential. By analyzing regional performance alongside technological advancements, the report provides a strategic framework that aligns localized market strategies with the overarching global trends in AMH testing.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights and Competitive Landscape

The competitive landscape of the AMH testing market is marked by a blend of established industry giants and dynamic newcomers, each contributing unique strengths and innovative practices. Notable companies such as Abbexa Limited, Ansh Labs LLC, and Athenese-Dx lead the market with their cutting-edge technologies and robust R&D initiatives. Global players including Bio-Rad Laboratories, Inc., Bio-Techne Corporation, and bioMerieux S.A. are leveraging their extensive portfolios to provide comprehensive diagnostic solutions.

Other key players such as BioVendor - Laboratorni Medicina A.S., Chengdu VACURE Biotechnology Co., Ltd., CTK Biotech, Inc., and Cusabio Technology LLC are gaining traction by focusing on niche segments and specialized assay development. Corporations like Danaher Corporation, Eagle Biosciences, Inc., and Elabscience Bionovation Inc. are continuously innovating, pushing the envelope with advanced instrumentation and high-sensitivity reagents.

Major entities such as Epitope Diagnostics, Inc., F. Hoffmann-La Roche Ltd., and Fujirebio Europe N.V. by H.U. Group Holdings, Inc. underscore the market's commitment to quality and accuracy. Additional influential companies include Goldsite Diagnostics Inc., Healthy Human Labs Limited (Vitall), Kamiya Biomedical Company, LifeSpan BioSciences, Inc., and London Gynaecology Limited, whose contributions have been instrumental in elevating market standards. Meridian Bioscience, Inc., Monobind Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tosoh Corporation, and Vitrosens Biotechnology Co., Ltd. further enrich this competitive mix. This diverse array of companies ensures that the market remains dynamic, continuously evolving through innovation and strategic collaborations.

The report delves into recent significant developments in the Anti-Mullerian Hormone Test Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Ansh Labs LLC, Athenese-Dx, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMerieux S.A., BioVendor - Laboratorni Medicina A.S., Chengdu VACURE Biotechnology Co., Ltd., CTK Biotech, Inc., Cusabio Technology LLC, Danaher Corporation, Eagle Biosciences, Inc., Elabscience Bionovation Inc., Epitope Diagnostics, Inc., F. Hoffmann-La Roche Ltd., Fujirebio Europe N.V. by H.U. Group Holdings, Inc., Goldsite Diagnostics Inc., Healthy Human Labs Limited (Vitall), Kamiya Biomedical Company, LifeSpan BioSciences, Inc., London Gynaecology Limited, Meridian Bioscience, Inc., Monobind Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tosoh Corporation, and Vitrosens Biotechnology Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to focus on several strategic initiatives to successfully navigate and thrive in the rapidly evolving AMH testing market. It is imperative to invest in the development and integration of advanced diagnostic technologies that enhance accuracy and reduce testing turnaround time. Embracing automation and digital health innovations can significantly streamline operational workflows, thereby optimizing overall efficiency.

Leaders should also prioritize the expansion of product portfolios to include both point-of-care and self-check testing options, catering to a diverse range of end users who have varied needs. The dual approach of refining instruments-whether through benchtop devices or portable analyzers-and innovating around reagents and kits, both customized and standard, can facilitate robust market penetration.

In addition, forging strategic partnerships with diagnostic laboratories, fertility clinics, hospitals, and research institutes can accelerate innovation and help in effectively addressing region-specific challenges. Keeping abreast of regional regulatory changes, and tailoring strategies accordingly, will further help in capitalizing on emerging market opportunities. Finally, enhancing consumer education about the clinical benefits of the AMH test can drive increased adoption, ensuring that both clinical practitioners and patients are well informed and confident about the diagnostic value of these tests.

Conclusion: Strategic Outlook for the AMH Testing Market

In conclusion, the AMH testing market is poised for significant transformation driven by technological innovations, evolving clinical standards, and a proactive approach to addressing patient needs. The integration of advanced diagnostic instruments with versatile assay kits has not only augmented testing accuracy but also redefined service delivery models across varied clinical settings. The comprehensive segmentation analysis reveals that innovations in product design, component flexibility, application specificity, and end-user engagement play an integral role in market evolution.

The regional outlook underscores distinct growth dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each contributing uniquely to global market performance. The competitive landscape, enriched by influential players spanning from established companies to emerging disruptors, reinforces the market's commitment to continuous innovation and high-quality diagnostics.

As the market evolves, stakeholders are challenged to remain adaptable and forward-thinking. The strategic recommendations outlined herein emphasize the importance of investment in R&D, technological integration, and customer-centric methodologies. This strategic outlook provides a robust framework for navigating the future, ensuring that industry leaders are well-equipped to harness emerging opportunities and drive sustainable growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of reproductive health issues and infertility driving demand for AMH testing
    • 5.1.1.2. Government initiatives and favorable reimbursement policies support AMH test uptake
    • 5.1.1.3. Growing inclination towards late pregnancies fuels the need for reliable fertility indicators
  • 5.1.2. Restraints
    • 5.1.2.1. High operational costs and limited reimbursement policies constrain the anti-mullerian hormone test market
  • 5.1.3. Opportunities
    • 5.1.3.1. Promoting AMH testing as an essential tool for personalized medicine within the broader fertility landscape
    • 5.1.3.2. Enhancing digital platforms for seamless AMH test booking and result management to improve user experience
  • 5.1.4. Challenges
    • 5.1.4.1. Significant regulations affecting the expansion of anti-mullerian hormone testing
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing demand for self-check kits for convenience and personal health management
  • 5.2.2. Applications: Expanding application of anti-mullerian-hormone-test for ovarian reserve assessment with rising fertility issues
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Mullerian Hormone Test Market, by Product

• 6.1. Introduction
• 6.2. POC Testing
• 6.3. Self-check Kits

7. Anti-Mullerian Hormone Test Market, by Component

• 7.1. Introduction
• 7.2. Instruments
  • 7.2.1. Benchtop Devices
  • 7.2.2. Portable Analyzers
• 7.3. Reagents & Kits
  • 7.3.1. Customized Assays
  • 7.3.2. Standard Assays

8. Anti-Mullerian Hormone Test Market, by Applications

• 8.1. Introduction
• 8.2. Ovarian Reserve Assessment
• 8.3. Polycystic Ovary Syndrome Diagnosis
• 8.4. Premature Ovarian Failure Prediction

9. Anti-Mullerian Hormone Test Market, by End User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Fertility Clinics
• 9.4. Hospitals
• 9.5. Research Institutes

10. Americas Anti-Mullerian Hormone Test Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Anti-Mullerian Hormone Test Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Mullerian Hormone Test Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Beli's launches at-home test kits revolutionize personalized reproductive health
  • 13.3.2. Siemens Healthineers introduced a Novel Assay for Assessing Ovarian Reserve
  • 13.3.3. ARUP Laboratories introduced MenoCheck to revolutionize menopausal management
  • 13.3.4. The Advent of the Elecsys Anti-Mullerian Hormone Plus immunoassay for Enhanced Accessibility and Early Detection
  • 13.3.5. Innovative At-Home Fertility Test by Fertilly for Understanding Reproductive Health through Anti-Mullerian Hormone Analysis
  • 13.3.6. Strategic Acquisition of Meridian Bioscience by SD Biosensor and SJL Partners for Enhanced Growth and Global Impact
  • 13.3.7. Randox Quality Control Introduces Advanced Acusera AMH Control for Enhanced Reproductive Testing
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbexa Limited
• 2. Ansh Labs LLC
• 3. Athenese-Dx
• 4. Bio-Rad Laboratories, Inc.
• 5. Bio-Techne Corporation
• 6. bioMerieux S.A.
• 7. BioVendor - Laboratorni Medicina A.S.
• 8. Chengdu VACURE Biotechnology Co., Ltd.
• 9. CTK Biotech, Inc.
• 10. Cusabio Technology LLC
• 11. Danaher Corporation
• 12. Eagle Biosciences, Inc.
• 13. Elabscience Bionovation Inc.
• 14. Epitope Diagnostics, Inc.
• 15. F. Hoffmann-La Roche Ltd.
• 16. Fujirebio Europe N.V. by H.U. Group Holdings, Inc.
• 17. Goldsite Diagnostics Inc.
• 18. Healthy Human Labs Limited (Vitall)
• 19. Kamiya Biomedical Company
• 20. LifeSpan BioSciences, Inc.
• 21. London Gynaecology Limited
• 22. Meridian Bioscience, Inc.
• 23. Monobind Inc.
• 24. Siemens Healthineers AG
• 25. Thermo Fisher Scientific Inc.
• 26. Tosoh Corporation
• 27. Vitrosens Biotechnology Co., Ltd.